Overall market sentiment has been down on Aileron Therapeutics Inc (ALRN) stock lately. ALRN receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.
Aileron Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ALRN!
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With ALRN Stock Today?
Aileron Therapeutics Inc (ALRN) stock has fallen -9.23% while the S&P 500 is higher by 4.5% as of 11:31 AM on Thursday, Nov 10. ALRN has fallen -$0.02 from the previous closing price of $0.18 on volume of 967,496 shares. Over the past year the S&P 500 is lower by -16.39% while ALRN has fallen -81.52%. ALRN lost -$0.17 per share in the over the last 12 months.
More About Aileron Therapeutics Inc
Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects.
Click Here to get the full Stock Report for Aileron Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
